Hennion & Walsh Asset Management’s Altimmune ALT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.58M Buy
518,198
+316,209
+157% +$944K 0.05% 445
2026
Q1
$622K Sell
201,989
-12,643
-6% -$53.7K 0.02% 647
2025
Q4
$775K Buy
214,632
+29,057
+16% +$127K 0.03% 586
2025
Q3
$700K Sell
185,575
-3,380
-2% -$13.1K 0.03% 605
2025
Q2
$731K Sell
188,955
-8,729
-4% -$47.2K 0.03% 567
2025
Q1
$988K Sell
197,684
-7,906
-4% -$50.1K 0.04% 476
2024
Q4
$1.48M Buy
205,590
+31,482
+18% +$241K 0.07% 358
2024
Q3
$1.07M Buy
174,108
+44,832
+35% +$304K 0.05% 438
2024
Q2
$860K Buy
+129,276
New +$954K 0.04% 459

Other funds holding ALT

Hennion & Walsh Asset Management's ALT Position: Q2 2026 in Review

Hennion & Walsh Asset Management increased its Altimmune (ALT) stake by 157% in Q2 2026, buying an estimated $944K and bringing the position to 518,198 shares worth $1.58M. The position accounts for 0.05% of the portfolio, ranked #445.

Hennion & Walsh Asset Management first reported a position in ALT in Q2 2024 and has held it in 9 quarters since. 14 funds tracked by Wall St. Rank hold ALT as of Q2 2026.

  • Hennion & Walsh Asset Management held 518,198 shares of Altimmune worth $1.58M as of Q2 2026.
  • Hennion & Walsh Asset Management bought 316,209 Altimmune shares in Q2 2026, an estimated $944K.
  • Altimmune made up 0.05% of Hennion & Walsh Asset Management's portfolio in Q2 2026, its #445 holding.
  • Hennion & Walsh Asset Management first reported a position in Altimmune in Q2 2024 and has held it in 9 quarters since.
  • 14 funds tracked by Wall St. Rank held Altimmune as of Q2 2026.

Based on Hennion & Walsh Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.